1. Overall tumour response to monotherapy treatment with adagrasib was 23% 46% in combination with...
Read More
1. There was some progression-free survival benefit in adding veliparib to cisplatin in patients...
Read More
1. Greater early-life body size is not an independent risk factor for colorectal cancer (aside...
Read More
1. In this randomized controlled trial, the post-test fatigue score was significantly lower in...
Read More
1. In this randomized controlled trial, religious psychotherapy was associated with significant...
Read More
1. In patients with KRAS p.G12C mutated pancreatic cancer, 21% had a partial response, and 0% had...
Read More
1. Prognostic markers of residual disease following a loop electrosurgical excision procedure for...
Read More
1. In this retrospective cohort study, adult patients with hepatitis C virus (HCV) infection...
Read More
1 .Tumor-infiltrating lymphocytes therapy shows improvements in PFS when compared to ipilimumab 2....
Read More
1. Fewer instances of clinically insignificant prostate cancer were identified in an experimental...
Read More
1. The post-hoc analysis of JUPITER-06 showed the superiority of adding toripalimab (PD-1...
Read More
1. This study found that a high proportion of Food and Drug Administration (FDA) drug trials...
Read More
1. OS in triplet combination therapy (atezolizumab, vemurafenib, and cobimetinib) while numerally...
Read More
1. Patients receiving autologous tumour lysate-loaded dendritic cell vaccine (DCVax-L) had a 20%...
Read More
1. In patients with a pancreatic or periampullary tumour undergoing pancreaticoduodenectomy (PD),...
Read More
1. In this phase 3 nonrandomized controlled trial, among 331 patients, patients with newly...
Read More
1. This retrospective study found that patients who experienced a same-day cancellation of their...
Read More
1. Around 30% of colorectal patients travel beyond their closest hospital site to undergo a...
Read More
1. Starting treatment with nivolumab/ipilimumab rather than dabrafenib/trametinib resulted in an...
Read More
1. Median overall survival was longer in patients receiving steroid-only treatment for adverse...
Read More
